ClinicalTrials.gg
TerminatedNCT01388920Updated Mar 18, 2022Results posted

Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting

A Phase 2 interventional study of Tesamorelin and Placebo in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Theratechnologies. Terminated. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-03-18.

Sponsored by Theratechnologies · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated based on a non-safety related corporate decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Study summary

A significant proportion of COPD subjects experience muscle wasting, which has been associated with increased morbidity, impaired physical functioning, and a poor quality of life.

Muscle wasting is associated with reduced muscle strength in COPD subjects. In particular, weakness of peripheral muscles has been reported to play an important role in the reduced functional capacity and impaired exercise performance.

The primary objective of this study is to investigate the effect of tesamorelin, in conjunction with exercise training, on lean body mass measured by dual energy x-ray absorptiometry (DXA) scan.

02

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • COPD
  • Muscle wasting
03

In context

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

This study's enrollment of 3 is below the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

Theratechnologies is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged 40-75 years (y) inclusive
  • Documented diagnosis of moderate to very severe (GOLD stage 2, 3, or 4)
  • Stable COPD (i.e., no exacerbation) for at least 6 weeks prior to screening
  • Able to participate in a supervised exercise training program
  • Evidence of muscle wasting

Exclusion criteria

Exclusion Criteria

  • Participation in a pulmonary rehabilitation program or in any supervised exercise program during the 4 months prior to screening
  • More than 4 exacerbations in the year prior to screening
  • Life-threatening exacerbation in the year prior to screening
  • Requirement for long-term oxygen therapy (> 12 hours of oxygen per day)
  • Critical illness or co-morbid conditions that may interfere with study conduct or endpoint measurements
  • Use of agents known to increase lean body mass within 3 months prior to screening
  • Hypopituitarism, history of pituitary tumor/surgery, head irradiation, or severe head trauma
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Tesamorelin 2 mg

    Tesamorelin 2 mg/day

    Drug: Tesamorelin

  • Experimental
    Tesamorelin 3 mg

    Tesamorelin 3 mg/day

    Drug: Tesamorelin

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Lean Body Mass at 6 Months

    The primary objective of the study was to evaluate the effect of tesamorelin on lean body mass by Dual-energy X-ray absorptiometry (DXA) scan

    Time frame: 6 months

Secondary outcomes

  1. Change From Baseline in Exercise Capacity at 6 Months

    Time frame: 6 months

  2. Change From Baseline in Peripheral Muscle Strength at 6 Months

    Time frame: 6 months

  3. Change From Baseline in Patient-reported Outcomes at 6 Months

    Time frame: 6 months

  4. Adverse Events

    Number and percentage of subjects with adverse events

    Time frame: 6 months

  5. COPD Exacerbations

    Frequency and severity of COPD exacerbations

    Time frame: 6 months

  6. Plasma Glucose

    Changes from baseline in fasting blood glucose

    Time frame: 6 months

07

Results

Posted May 7, 2014

Participant flow

Participant flow — Overall Study
MilestoneTesamorelin 2 mgTesamorelin 3 mgPlacebo
Started110
Completed110
Not completed000

Outcome measures

PrimaryChange From Baseline in Lean Body Mass at 6 Months

The primary objective of the study was to evaluate the effect of tesamorelin on lean body mass by Dual-energy X-ray absorptiometry (DXA) scan

Time frame:
6 months

No measurements were reported for this outcome.

SecondaryChange From Baseline in Exercise Capacity at 6 Months
Time frame:
6 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Peripheral Muscle Strength at 6 Months
Time frame:
6 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Patient-reported Outcomes at 6 Months
Time frame:
6 months

Results for this outcome have not been posted.

SecondaryAdverse Events

Number and percentage of subjects with adverse events

Time frame:
6 months

Results for this outcome have not been posted.

SecondaryCOPD Exacerbations

Frequency and severity of COPD exacerbations

Time frame:
6 months

Results for this outcome have not been posted.

SecondaryPlasma Glucose

Changes from baseline in fasting blood glucose

Time frame:
6 months

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tesamorelin 2 mg—0/1 (0%)0/1 (0%)
Tesamorelin 3 mg—0/1 (0%)0/1 (0%)
Placebo———

Baseline characteristics

Age, Continuous
Age, Continuous(years)Tesamorelin 2 mgTesamorelin 3 mgPlaceboTotal
Mean59 ± 051 ± 0—55 ± 0
Sex: Female, Male
Sex: Female, Male(Participants)Tesamorelin 2 mgTesamorelin 3 mgPlaceboTotal
Female01—1
Male10—1
Region of Enrollment
Region of Enrollment(participants)Tesamorelin 2 mgTesamorelin 3 mgPlaceboTotal
United States11—2
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2011
First posted
Jul 7, 2011
Start
Sep 2011
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Results first posted
May 7, 2014
Last update
Mar 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01388920
Lead sponsor
Theratechnologies
Responsible party
Sponsor
First posted
Jul 7, 2011
Start date
Sep 2011
Primary completion
Dec 2011
Completion
Dec 2011
Results posted
May 7, 2014
Last update
Mar 18, 2022

Study contacts

Richard Casaburi, PhD, MD
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tesamorelin

Start the discussion